Research programme: autoimmune and inflammation therapeutics - Zymeworks
Latest Information Update: 21 Sep 2016
At a glance
- Originator Zymeworks
- Class Anti-inflammatories; Antibodies; Proteins
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Inflammation
Most Recent Events
- 19 Sep 2016 Early research in Autoimmune disorders in Canada (Parenteral)
- 19 Sep 2016 Early research in Inflammation in Canada (Parenteral)